Long-term safety and effectiveness of tulisokibart for Crohn's or colitis
Treatments studied
Part of Digestive system clinical trials.
This study gives tulisokibart to people who already took part in an earlier trial for Crohn's disease or ulcerative colitis and are still benefiting from it. The goal is to see how safe and effective the medicine is over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in a previous study of tulisokibart for Crohn's disease or ulcerative colitis.
- Your doctor agrees that tulisokibart is helping you and you should keep taking it.
- If you are able to become pregnant, you are not pregnant or breastfeeding, and you use birth control or do not have penis-vagina sex.
- You did not stop the study drug early in your previous study.
- You did not take any medications that were not allowed during your previous study.
- You are not allergic to tulisokibart or any of its ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the long-term safety and side effects of an investigational drug called balinatunfib in people with Crohn's disease or ulcerative colitis. It is for patients who have already completed a full year of treatment in a previous related study.
This Phase 1 trial tests a new drug called LMT503 in adults to learn its safety, tolerability, and how the body handles it. If you qualify, you may receive the study medicine in a controlled research setting with regular checkups and blood/heart monitoring.
This study tests several new treatments to see if they are safe and helpful for people with moderate to severe ulcerative colitis. If you have not responded well to standard treatments, this might be an option.
This trial tests a medicine called afimkibart for children with moderately to severely active Crohn's disease. It aims to see how well the drug works and how safe it is when used for both starting and ongoing treatment.
This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.
This trial tests a new drug called tulisokibart for people with psoriatic arthritis (PsA), a condition that causes joint pain and skin plaques. It may help if you have not tried certain biologic medications or if they did not work well.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.